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Abstract
Plant sterols are naturally occurring molecules that humanity has evolved with. Herein, we have
critically evaluated recent literature pertaining to the myriad of factors affecting efficacy and safety
of plant sterols in free and esterified forms. We conclude that properly solubilized 4-desmetyl plant
sterols, in ester or free form, in reasonable doses (0.8–1.0 g of equivalents per day) and in various
vehicles including natural sources, and as part of a healthy diet and lifestyle, are important dietary
components for lowering low density lipoprotein (LDL) cholesterol and maintaining good heart
health. In addition to their cholesterol lowering properties, plant sterols possess anti-cancer, anti-
inflammatory, anti-atherogenicity, and anti-oxidation activities, and should thus be of clinical
importance, even for those individuals without elevated LDL cholesterol. The carotenoid lowering
effect of plant sterols should be corrected by increasing intake of food that is rich in carotenoids.
In pregnant and lactating women and children, further study is needed to verify the dose required
to decrease blood cholesterol without affecting fat-soluble vitamins and carotenoid status.
Background
Plant sterols are plant compounds with similar chemical
structure and biological functions as cholesterol [1]. Plant
sterols contain an extra methyl, ethyl group or double
bond. The most abundant plant sterols are sitosterol,
campesterol and stigmasterol [2]. The daily dietary intake
of plant sterol is 160–400 mg among different popula-
tions [3-9]. However, in the earlier stages of human evo-
lution, some 5–7 million years ago, plant sterol intake in
Myocene diets would have been considerably higher, up
to 1 g/d [10]. Dietary sources include vegetable oils (espe-
cially unrefined oils), nuts, seeds and grains [1]. Absorp-
tion efficiency for plant sterols in humans is considerably
less than that of cholesterol. Percent absorption of the
former is 2–5% [11] versus 60% for the latter [12]. Conse-
quently, blood levels of plant sterols in humans are only
0.1–0.14% of cholesterol levels [13]. Due to their struc-
tural similarity to cholesterol, plant sterols were first and
foremost studied for their cholesterol absorption inhibi-
tion properties. In addition to their cholesterol lowering
effect, plant sterols may possess anti-cancer [14], anti-
atherosclerosis [15,16], anti-inflammation [17] and anti-
oxidation activities [18]. The objective of the present
review is to assess the evidence supporting the various
physiological effects of plant sterols with emphasis on
recent advances in knowledge.
Physiological effects of plant sterols
Cholesterol lowering actions
The cholesterol lowering effect of plant sterols is well doc-
umented in the literature. It is now accepted, after much
earlier scientific debate and study, that 4-desmethyl plant
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sterols or stanols, either in their free or esterified form,
decrease blood levels of total cholesterol and LDL-choles-
terol through reduction of cholesterol absorption. Gener-
ally speaking, properly solubilized free sterols and
esterified sterols possess similar cholesterol lowering abil-
ity [19,20]. In some studies such comparisons have been
Table 1: Effects of free sterols and stanols on LDL cholesterol and cholesterol absorption parameters.
Reference Products Vehicle Subject Condition: 
Starting mean 
TC mM
Daily Dose g 
Free sterol/
stanol 
Equivalents
#Servings/d Outcome: Where possible, 
Placebo-adjusted % decrease LDL 
is given = % decrease with sterol 
(To vs Tf) % decrease with placebo 
(To vs Tf). C-abs also indicated
[59] A2
C2
Spread 9 Normocholesterol
emic
1.0
1.3
↓ C-abs 42.0%
↓ C-abs 33.0%
[176] B2 Sunflower  oil 
(Capsule)
3 M, 3 W Hypercholesterole
mic
1.5 ↓ LDL 14.4%
[27] A1
B1
Mayonnaise 24 M&W 6.5 0.96
1.0
Habitual usage ↓ TC 5.7%
↓ TC 2.4%
[28] A1
B1
D1
Mayonnaise 22 M, 9 W >6.0 1.0
1.0
1.2
Habitual usage ↓ LDL 6.2%
↓ LDL 5.1%
↓ LDL 7.7%
[21]  B1+step 1 diet Capsules with 
sterols 
consumed with 
food
33 M 6.2 3.0
3.0 with 8 g 
cholestyramine 8 g 
of cholestyramine
3 ↓ LDL 1.8%
[33] A2 Spread 12  M Normocholesterol
emic
0.7 ↓ LDL 6.1%
[177]  A2 olive oil 8 M, 8 W 3.7 M, 4.1 W 0.4 g/1000 Kcal 3 ↓ LDL 2.8%
[103] A1 Spread 22 5.0  minimum 1.6 ↓ LDL 15 % Normocholesterolemics
↓ LDL 4.7% hypercholesterolmics
[97]  B1+prudent diet Spread 32 M 6.7–6.8 1.7 3 ↓ LDL 15%
[22]  B2 +soylecithin Spread 4 M, 2 W 5.2 1.0-B2 powder
0.3–0.7-B2/lecithin 
micellar mix
↓ C-abs 11.0%
↓ C-abs 34.4% at 0.3 g
↓ C-abs 36.7% at 0.7 g
[20]  A2 Spread 39 M, 37 W 4.9–5.1 0.8 Habitual usage ↓ LDL 6%, ↓ TC 9%
[69] B1 Liquid  emulsion 12  M 6.9 3 3 ↓ C-abs 40%
[100] A1
B1
1:1 mixture
A1:B1
Butter fat ± 
sterols
9 M, 6 W 6.5 1.8 3 ↓ LDL 13.3%, ↓ C-abs 56.1%
↓ LDL 13.4%, ↓ C-abs 33.3%
↓ LDL 16.0%, ↓ C-abs 49.2%
[44] A2 Vegetable  oil, 
partly filled 
milk
18 M 7.0 1.8 2 ↓ C-abs 39%
[71] A2 Vegetable  oil, 
partly filled 
milk
33 M <5.2 2.2 2 ↓ C-abs 51.1%
[42] A2 Vegetable  oil, 
partly filled 
milk
18 M, 51 F 7.0 1.2 or 1.6 2 ↓ LDL 7.1% at 1.2 g
↓ LDL 9.6% at 1.6 g
Abbreviation: C-abs, cholesterol absorption; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol; To and Tf refer to start and end 
points of the study; M, men; W, women; A, free plant sterol; B, free plant stanol; C, plant sterol ester; D, plant stanol ester; 1, tall sterol; 2, soy 
sterol; 3, shea sterol; 4, corn sterol; 5, rice sterol.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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Table 2: Effects of esterified sterols and stanols on LDL cholesterol and cholesterol absorption.
Reference Products Vehicle Subject Condition: 
Starting mean 
TC mM(range)
Daily Dose g Free 
sterol/stanol 
Equivalents
#Servings /d Outcome: Where possible, 
Placebo-adjusted % decrease 
LDL is given = % decrease with 
sterol (To vs Tf) % decrease with 
placebo (To vs Tf)
[32]  D1 Mayonnaise 11 M, 4 W >6.0 0.8 2.0 Habitual usage ↓ LDL 7.7%
↓ LDL 15.0%
[102]  D1 Spread rapeseed 153 M&W 5.9–5.9 1.8 or 2.6 3 ↓ LDL 10.2%
[25] C2  (66% 
esterified), D1-2, 
C3, C5
Spread 100 <8.0 3.3 D1-2
3.3 C2
1.5 C3
1.5 C5
2 ↓ LDL 13%
↓ LDL 13%
↔ LDL
↔ LDL
[178]  CD1 Spread 23 W 5.5–8.0 2.4, 3.2, 3.2 ↓ LDL 8–10%
↑ HDL 5–6%
[104] D2
D1-2
Spread, low fat 
diet
20 M, 35 W 6.1–6.6 2.2
2.3
↓ LDL 13.7%
↓ LDL 8.6 %
[104]  C2 Spread 42 M, 58 W 5.2(2.7–7.4) 0.8
1.6
3.2
2 ↓ LDL 6.2 %
↓ LDL 9.2 %
↓ LDL 9.8%
[76] C2
D1
Spread 34 M&W 4.8–7.0 2.0 2 ↓ LDL 10.4%
↓ LDL 12.7%
[37]  D1-2 Spread 14 M, 8 W 6.9(5.0–8.5) 0.8
1.6
2.4
3.0
2–3 ↓ LDL 1.7%
↓ LDL 5.6%
↓ LDL 9.7%
↓ LDL 10.4%
[98] D1-2 Spread 105 6.0–6.6.1 2.0
3.0
2
3
↓ LDL 8.9%
↓ LDL 6.7%
[77] C1
D1
Spread 15 M 6.4–6.5(6.0–10.0) 1.8
1.8
2–3 ↓ LDL 13.4%, ↓ C-abs 36.2%
↓ LDL 6.4%, ↓ C-abs 25.9 %
[179]  C2, D1-2 Spread 5 M, 2 W Illeostomy 1.5 ↓ C-abs 38–39%
[99] D2
D1-2
Spread 41 M, 71 W 5.0–5.1 3.8
4.0
3 ↓ LDL 12.6%
↓ LDL 1.6%
[96]  D1-2 Spread 11 M, 28 W 4.9 M, 4.7 W 2.5-different # 
servings
1
3
↓ LDL 9.9
↓ LDL 10.2%
[38]  C2 Spread, Step 1 
diet
224 M&W 6.2 1.1
2.2
2 ↓ LDL 4.9%, ↓ TC 2.6%
↓ LDL 5.4%, ↓ TC 4.0%
[78]  C (mainly 2) Spread 34 M, 28 W 7.2 (control) 6.5 
(treatment)
2.5 ↓ LDL 10–15%
[73] C2 Beef 34  M 5.9 2.4 1 ↓ LDL 15%
[70]  D Yoghurt 16 M, 44 W 5.1 3.0 3 ↓ LDL 14 %
[65]  C Spread 25 M, 38 W 6.1 1.8 2 ↓ LDL 5.4%, ↓ TC 3.4%Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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flawed because the free sterols were not properly solubi-
lized [21]. Ostlund et al. [22] showed that emulsions of
sitostanol, mixed with lecithin containing 0.7 g of sterol,
reduced cholesterol absorption considerably, whereas less
effect was seen with sitosterol in crystalline form.
This review will focus on the effects of 4-desmethyl ster-
ols, stanols, and esterified forms. Methylated sterols (4α-
monomethyl and 4,4-dimethyl) in sources such as shea
and M. alpina fungi for example, and those sterols esteri-
fied to non-fatty acids such as ferulate (such as the sterols
in rice bran oil), may not be equivalent in cholesterol low-
ering ability compared with the forms present in tall and
soybean oils [19,20,23-26].
Important issues that remain to be verified regarding the
cholesterol lowering effect of plant sterols includes (i) effi-
cacy of low dose of plant sterols, (ii) the effect diet back-
ground on plant sterol efficacy, (iii) the efficacy of plant
sterols when incorporated in food other than fat spread
(iv) the optimal number of plant sterols servings and (v)
the relative efficacy of plant sterols among different
populations.
Efficacy of low dose of plant sterols
Tables 1 and 2 summarize recent human intervention
clinical trials assessing the effects of 4-desmethyl free and
esterified plant sterols. Doses of plant sterols reported in
literature are often difficult to comprehend, particularly
those reported in earlier literature. Herein, all doses refer
to free plant sterol equivalent doses. If the contribution of
naturally occurring plant sterols in the food vehicle was
reported, this is then added to the free plant sterol dose.
Ideally, the free plant sterol dose should be calculated
experimentally using the average mol% of fatty acids rela-
tive to free sterols.
Selected studies 1990–1994
Vanhanen and Miettinen [27] in 1992 found a dose of
0.95 g of sitosterol per day, including the contribution of
free sterols present in the canola oil used to prepare the
basal spread, probably consumed in 2–3 doses, did not
result in reduction in total cholesterol compared to con-
trol group. LDL cholesterol typically follows changes in
total cholesterol, sometimes being more responsive to
plant sterol modulation. Since the control spread con-
tained 0.36 g of rape seed oil derived sterols, a level of
consumption by vegetarians, the study is essentially com-
paring vegetarian levels of consumption of plant sterols to
a 3-fold higher level. The conclusion from this study alone
would be that a higher dose than 0.95 g of free sterols
should be considered to achieve a more consistent and
effective lowering of LDL cholesterol levels. In another
study with a design similar to that of Vanhanen and Miet-
tinen [27], the absolute reduction in LDL cholesterol was
only statistically significant for the sitostanol esters, which
showed slightly better efficacy than the free sterols and
stanols [28]. The dose of 1.0 g sitosterol reduced choles-
terol absorption more effectively than the control spread.
This is not surprising because absorption is known to be
an extremely sensitive marker that does not necessarily
correlate to changes in LDL cholesterol levels [7,29-31].
Even basal levels of consumption of plant sterol are corre-
lated with cholesterol absorption.
Vanhanen et al [32] showed that in mildly hypercholeste-
rolemic men and women of age 33–60, 1.2 g of free tall
stanol equivalents in mayonnaise decreased LDL levels by
7.7%. Relative to starting levels for this group, this reduc-
tion was statistically significant, but the absolute lowering
of LDL was not statistically significant after accounting for
reductions in LDL cholesterol observed with the control
group. The lack of statistical significance in LDL lowering
is not surprising because the total sample size was only 15
persons, and there was appreciable plant sterol, about 0.4
g, in the control mayonnaise, which probably reduced
LDL cholesterol as well. The quantity of plant sterols in
the control spread complicates interpretation of results
and makes comparisons to other scientific studies more
difficult.
[79] C  (vegetable  oil) Spread,  Japanese 
basal diet
26 M, 27 W 5.5 1.8 2 ↓ LDL 9.2%, ↓ TC 5.8%
[80]  C (vegetable oil) Spread 19 M, 31 W 6.0 2.1 ↓ LDL 12.3%, ↓ TC 8.9%
[180]  D Spread 38 M, 22 W 6.1 (2 g group)
6.0 (3 g group)
2.0
3.0
2
3
↓ LDL 9.6%, ↓ TC 6.3%
↓ LDL 7.3%, ↓ TC 5.5%
[71] C2 Vegetable  oil, 
partly filled milk
33 M <5.2 2.2 2 ↓ C-abs 57.4%
See Table 1 for abbreviations.
Table 2: Effects of esterified sterols and stanols on LDL cholesterol and cholesterol absorption. (Continued)Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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Selected studies 1995–1999
Pelletier et al. [33] demonstrated that 0.7 g of soy sterols
in spreads fed to 12 normocholesterolemic individuals
reduced LDL cholesterol by 15.2% relative to the control.
In another study [20], a dose of 0.8 g of soy sterols fed to
76 normocholesterolemic individuals reduced LDL cho-
lesterol by 6.1% relative to the control, and more impor-
tantly, did not reduce carotenoids or carotenoids
normalized to cholesterol, as reported by Hendriks et al.
[19] with a similar dose of soy free sterol equivalents,
administered as an ester. The LDL reductions reported by
Sierksma et al. [20] were less than that seen in the Pelletier
et al. [33] study, which used a similar dosage. The
reduction in LDL in the Seerksma study was not seen in all
subjects because of the well-known within person LDL
variation of 10% [34] or solubilization issues. Neverthe-
less, this 6% reduction in LDL correlates with a 15%
reduction in CHD risk at age 40, and a 6% reduction at
age 70 [35] or a 10% reduction [36].
Hendriks et al [19] showed that in men and women with
a wide range of ages and starting total cholesterol from
low/normal to high, 0.83 g of free soy sterol equivalents
in spreads decreased LDL cholesterol 6.2%. Interestingly,
0.83 g was less effective than the two higher doses,1.6 and
3.2 g of sterol equivalents, at reducing LDL cholesterol,
but the differences amongst the three doses were not sta-
tistically significant. This study thus gives strong indica-
tion that a 0.8 g free sterol equivalent dose of plant sterols
can efficaciously diminish LDL cholesterol. Nevertheless,
the authors concluded that the 1.6 g dosage is most desir-
able because of the lack of effect on lipid normalized car-
otene, and the quantitatively greater reduction in LDL
cholesterol.
Selected studies 2000–2004
Hallikainen et al. [37] showed that in normal to mildly
hypercholesterolemic men and women, 0.8 g of free tall/
vegetable stanol equivalents in spreads decreased LDL
non-significantly by only 1.6%. This 0.8 g dose did reduce
the number of apo B particles by 8.7%, indicating a
reduced number of LDL particles. Similar to Vanhanen et
al. [32], the higher dose of 1.6 g of stanol equivalents
reduced LDL cholesterol to a greater extent of 6.1%, and
two higher doses (2.4 and 3.2 g/d) reduced LDL choles-
terol 10.6–11.5%. The three higher doses (1.6–3.2 g/d)
lowered LDL cholesterol in a statistically significant man-
ner. A caveat in this study was that the 0.8 g/d dose was
given after cholesterol was already lowered by 3 subse-
quent plant sterol treatments, possibly producing bias
against seeing a reduction in LDL cholesterol with 0.8 g/d.
Albeit the above experimental weakness, the conclusion
would be that the dose of 1.6 g/d of stanol equivalents is
a more optimal dose for LDL cholesterol reduction.
Maki et al. [38] administered mildly hypercholestero-
lemic men and women 1.1 g/d of free tall sterol equiva-
lents in spreads, fed as sterol esters in two doses, which
decreased LDL levels by 4.9% while 2.2 g/d of sterol
equivalents decreased LDL by 5.4%.
Christiansen et al. [39] reported an 11.3% reduction in
LDL cholesterol after 6 months with 1.5 g/d of microcrys-
talline free sterols in spreads. No additional improvement
was seen with 3.0 g/d of plant sterol.
Volpe et al. [40] reported a 6.3% placebo-adjusted
decrease in LDL cholesterol after 4 wks with 1.0 g/d and a
greater reduction of about 12.2% with 2 g/d after 4 wks.
De Graaf et al. [105] found an intake of 1.8 g/d of free ster-
ols in chocolates to decrease LDL cholesterol 8.9% relative
to baseline.
Thomsen et al. [42] examined effects of non-esterified,
non-hydrogenated, soy bean derived plant sterols, solubi-
lized in a partly vegetable oil filled low fat milk on serum
LDL cholesterol in 81 mildly hypercholesterolemic Dan-
ish patients, in a double-blind, randomised, placebo-con-
trolled 3-arm cross-over study. Subjects consumed
habitual diets, with some restrictions on consumption of
fat and cholesterol rich foods. Subjects received 0, 1.2, or
1.6 g/d of sterols in two servings of 250 mL milk for 12
wks (4 wks/dose). The placebo-adjusted mean reduction
in LDL was 7.1 ± 12.3 and 9.6 ± 12.4% (mean ± SD) for
groups receiving 1.2 and 1.6 g of plant sterols, respec-
tively, with no differences between sexes. There was no
statistically significant difference in LDL lowering
amongst the 1.2 and 1.6 g/d groups, although Apo B was
decreased more with 1.6 than 1.2 g/d of sterols. Apo B is
an index of LDL particle number, thus the higher dose
may have decreased numbers of LDL particles more than
the lower dose. Differences in numbers of small, dense,
atherogenic LDL particles and LDL oxidization [43] are
other important future parameters to assess. It is notewor-
thy that there were 20–23% non-responders in the two
sterol groups, which was partially consistent with the large
differences in cholesterol absorption inhibition observed
with similar milk products containing plant sterols [44].
Thus, renewed attention should be given to the issue of
non-responders. Another noteworthy observation was the
randomization order in which the three milk products
affected the magnitude of the LDL lowering results, but
not the overall statistical findings. The placebo-adjusted
mean percentage decrease in LDL was more pronounced
with certain randomixation sequences compared to oth-
ers. This consideration is typically ignored in reporting
results of plant sterol clinical trials examining cholesterol
lowering efficacy.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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In a very recent study still in press [45], 72 men and
women aged 20–73 received two 8 ounce servings of
Minute Maid brand non-fat orange juice with breakfast
and dinner meals, providing 2 g/d of Cargill CoroWise
plant sterols for 8 wks. LDL was reduced 12.4% compared
to baseline and placebo; HDL and triacylglycerol levels
were not changed. The authors speculate that the fat in the
meals may help to emulsify the plant sterols in the orange
juice.
Effects of naturally occurring plant sterols
The effects of naturally-occurring plant sterols on choles-
terol metabolism have also been studied in both older
and more recent literature. It was reported that the
differences between effects of different plant oils on blood
lipid profiles may be related to their content of plant ster-
ols [46-49]. Indeed, there has been renewed interest in the
cholesterol lowering properties of speciality grains and
unprocesses oils rich in plant sterols including amaranth
oil [50,51], rice bran oil [52] (Berger et al., submitted),
avocado oil [53], extra virgin olive oil [54], macadamian
nut [55], and argan oil [56].
Ostlund et al. [49] showed that doses as low as 150–300
mg of naturally present corn oil-derived phytosterols can
reduce dietary cholesterol absorption. Also, it was shown
that the consumption of original wheat germ, which con-
tains about 328 mg plant sterols, reduced the cholesterol
absorption by 42.8 % compared to plant sterol-free wheat
germ [57]. These results indicate that naturally available
plant sterols are biologically effective as plant sterol sup-
plementation in reducing cholesterol absorption, and that
natural plant sterols have important effects on cholesterol
metabolism [57].
Summary of biologically active dose of plant sterols for optimal 
cholesterol lowering
Several studies [19,20,28,32,33,40,58] using intakes of
800–1000 mg of plant sterols per day have shown biolog-
ically/clinically significant (5% or more) reductions in
LDL cholesterol levels, relative to control, or at least
showed a statistically significant treatment effect relative
to the starting LDL cholesterol level at the beginning of
the treatment period, independent of control. Other stud-
ies [27,37] with a similar dosage range did not meet the
above criteria for biological reduction of LDL levels, or
achieve statistical significance. Some studies showed that
800–1000 mg/d of free plant sterol equivalents can
decrease the absorption of cholesterol, which is indica-
tive, but not necessarily predictive, of actual LDL choles-
terol lowering [22,28,32,59].
It has been shown that increasing the dosage beyond 1000
mg per day of free sterol equivalents increased LDL cho-
lesterol lowering efficacy or consistency of response lead-
ing to more statistically significant results [32,37,40].
Increasing the dosage beyond 1000 mg per day of free
sterol equivalents did not further increase LDL cholesterol
lowering efficacy [19].
In humans, there is a good likelihood that a dose of 0.8–
1.0 g of free sterol equivalents per day, properly solubi-
lized, administered in 2–3 servings with a meal, will
reduce LDL cholesterol by 5% or more and that this reduc-
tion in LDL cholesterol will correlate with an approximate
6–10% reduction in CHD risk at age 70 [35,36]. However,
at this dosage level, it is likely that not all individuals will
achieve a 5% reduction in LDL cholesterol [20].
Clinical relevance of LDL-cholesterol-lowering by plant sterols
As previously noted, it is generally agreed that high blood
cholesterol level (especially LDL cholesterol) is a risk fac-
tor for coronary heart disease (CHD). Oxidation of excess
LDL cholesterol leads to arterial wall plaque build up,
which then restricts blood flow and increases blood pres-
sure. Unless, hypercholesterolemia and hypertension are
treated, these factors are associated with increased risk of
coronary heart disease (myocardial infarction) and stroke
[35].
Therefore, the clinical relevance of LDL-cholesterol lower-
ing lies in the potential for plant sterols to reduce the
actual risk of CHD. As already described, there is an
impressive body of scientific data demonstrating choles-
terol-lowering by plant sterols. However, it is pertinent to
tease out from published studies, those providing the
highest level of evidence for a clinically-important effect.
Two reviews have addressed this issue [60,61]. Law [60]
estimated that consumption of 2 g of equivalents of plant
sterol or stanol per day would reduce heart disease risk
25%. But only a randomized clinical trial using CHD as
an endpoint, could provide certainty of the effectiveness
of plant sterols in reducing heart disease incidence. But for
a clinical trial to detect a 12–20% reduction in coronary
heart disease incidence would require 10,000–15,000
patients with CHD (and more for healthy people). Even if
such a trial were feasible, it would probably still be under-
powered to detect any rare adverse events (undesirable
side effects) [61]. Thus, we must judge the effectiveness of
plant sterol doses on their theorized ability to reduce
CHD incidence, using LDL cholesterol as a marker.
Low fat versus high fat background diet
Dietary cholesterol consumption is 250–500 mg/d, and
normally half is absorbed, while bilary cholesterol pro-
duction is 600–1000 mg/d. Since plant sterols impair the
absorption of both bilary and dietary cholesterol, it is not
surprising that they are effective even when consumed in
low fat diets [62,63], although evidence from some stud-
ies suggests them to be more effective when consumedLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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with diets containing cholesterol [21,64,65]. In a study by
Denke [21], plant stanols were given in capsules and not
blended with fatty matrix, which limits their cholesterol-
lowering action. In addition, compliance was monitored
by capsule counting and not by direct supervision, which
decreased compliance monitoring. Mussner et al. [65]
found esterified phytosterols in spreads to reduce LDL
cholesterol about 5.4%, but the reduction was 11.6% in
those tertiles having the highest intake of dietary choles-
terol. Recent studies have shown plant sterols to be effec-
tive even if consumed with Step I diets [38,40,66].
Similarly, Judd et al. [67] showed that high doses of vege-
table oil sterol esters lowered LDL cholesterol to about the
same level, whether the basal diet was a typical American
diet or a Step I type of diet, suggesting dramatic changes in
usual fat intake are not necessary, if plant sterols are con-
sumed concurrently.
Vehicle for delivering plant sterol
Most clinical trials have been conducted using plant ster-
ols or stanols added to spreads. As long as plant sterols are
consumed with a meal to stimulate biliary flow, they can
effectively lower LDL cholesterol on the background of
various types of basal diets and food vehicles. Plant sterols
are efficacious when consumed in: oil: water emulsions
[68,69]; water as lecithin micelles [22]; yogurt [40,70];
low fat filled milks [42,44,71]; chocolate [105]; cereal;
snack bars, breads, and beverages [66,72]; and beef/ham-
burger [73,74]. Efficacy of a soy stanol-lecithin powder in
reducing cholesterol absorption and LDL-C has been
evaluated in a randomized, double-blind parallel study
[75]. The subjects who followed a Step I diet consumed
soy stanol-lecithin powder in a beverage. The provided
daily dose of plant stanols was 1.9 g. The reductions in
blood cholesterol and LDL cholesterol were 10.1 and
14.4%, respectively. In another group of subjects, choles-
terol absorption was measured using 625 mg stanols pro-
vided in beverage or egg whites. Stanol-lecithin reduced
cholesterol absorption by 32.1% and 38.2 % when con-
sumed in beverage and egg white, respectively.
The reduction in LDL cholesterol reported, using the pre-
vious different vehicles, ranged between 7–14 %, which is
close to the reduction in LDL cholesterol reported in stud-
ies that used fat spread as a vehicle for delivering plant
sterol [25,37,76-82]. A recent controlled clinical trial has
shown that the intake of plant sterols provided in low-fat
and non-fat beverages did not affect lipid profiles in mod-
erately hypercholesterolemic individuals [83]. The find-
ing of this study was contrary to the findings of other
studies reporting that plant sterols were effective in reduc-
ing blood cholesterol even when incorporated into low-
fat or non-fat foods [40,42,44,70,72]. This discrepancy
may be related to the fact that the plant sterols must be
added to the low or non fat food matrix in such a way that
the plant sterols solubilize, or remain as small crystals
over time. In products such as milk, the milk fat globule
membrane components may enhance the absorption of
cholesterol [44,68,69], but also aid in solubilization. Pou-
teau et al. [44] described a rapid filtration and detection
method to quantify plant sterol crystals. The authors also
used light scattering techniques to quantify the size of the
crystals as a function of storage time of the milk products.
The method of dispersion, processing, and use of emulsi-
fiers, surfactants, and crystal habit modifiers will affect the
success of plant sterols in non-spread vehicles
[42,44,71,84,85].
Commercially, plant sterols are currently contained in
bars (Logicol-Australia, Benecol-UK), vegetable oils
(Ekona-Japan; NutraLease Canola Active-Israel), orange
juice (Minute Maid Heart Wise containing Cargill CoroW-
ise plant sterols) [45], mayonnaises (Logicol-Australia),
milk (Benecol-UK, Logicol-Australia, SereCol-Argente-
nia), yogurt (Logicol-Australia; Benecol-UK), yogurt
drinks (Benecol), soy milk (Pacific Foods), meat and
soups (Raisio-Finland), and green teas (Chol zero, Korea).
Plant sterols are also being sold or developed mixed with
other functional ingredients such as: fiber (Unilever Fruit
D'or-France); healthy oils (Benecol Olive Spread-UK);
non-absorbable diacylglycerol (Kao-ADM Econa Healthy
Cooking Oil; Enzymotec MultOil Platform, ArteriCare
products, Israel); almonds, soy protein and viscous fibers
[86]; and minerals [87-89]. There is also interest to com-
bine plant sterols with antioxidants, such as flavonoids,
quercetins, and catechin; and a spice mixture developed
by Selako, and marketed as Flavomare in Scandanavia. It
is only a matter of time before ingredients such as conju-
gated linoleic acid (CLA) are mixed with plant sterols in
various vehicles (e.g., Clarinol's CLA has received GRAS
status for addition to milks, yogurts, bars, etc.).
Various manufacturers also sell plant sterols in supple-
ment form, and there is interest to develop plant sterols as
drugs (e.g., Forbes' FM-VP4 drug candidate). Plant sterols
may also be combined with other drugs that lower choles-
terol through different mechanisms of action, including
statins and ezetimibe [90,91]. Recent evidence suggests
that patients who had previous actue coronary syndrome
benefited from aggressive LDL lowering with statins to
levels subtstantially below current target levels [92,93].
This finding provides enthusiasm for developing novel
plant sterol-drug and drug-drug combined strategies to
aggressively lower LDL cholesterol in some populations.
Despite evidence that plant sterols can effectively reduce
LDL cholesterol and inhibit cholesterol absorption in
vehicles other than spread type vehicles, regulatory agen-
cies have been slow to accept plant sterols in foods other
than spreads in some countries such as the USA [94] and
Australia [95]. Rigorous efforts underway by foodLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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companies and other highly respected organizations to
allow claims for plant sterols in foods other than spreads.
Optimal number of servings
It has been suggested that plant sterols should be con-
sumed at each cholesterol containing meal to achieve an
optimal effect. A daily intake of 2.5 g plant stanol esters,
either consumed once per day at lunch, or divided over
three portions resulted in a similar decrease in serum total
and LDL cholesterol levels [96]. Similar efficacy with a sin-
gle larger dose sterol esters has also been demonstrated in
two additional studies [73]. A single serving of yogurt,
providing 1 g of pure free sterols, resulted in a placebo-
adjusted reduction in LDL cholesterol of 6.3% [40]. Con-
sumption of a single dose of 2.4 g/d plant sterols resulted
in a 9.3 and 14.6 % reductions in blood total and LDL
cholesterol levels, respectively, in hypercholesterolemic
individuals [73]. Single doses of plant sterols may have
sustained effects on cholesterol absorption via interac-
tions with intestinal proteins (see Section 3.1.5.1 for
details).
Nevertheless, as there are a plethora of studies showing
the efficacy of plant sterols distributed in 2–3 meals
[19,25,37,38,70,76-82,97-100], and only two studies to
date demonstrating efficacy with a single larger serving
[73,96], it seems prudent to remain consistent with the
more established, conservative recommendation of con-
suming plant sterols in 2–3 doses with food, as adopted
by the United States FDA.
Population under study
Plant sterol for the adult population
Typically, cholesterol lowering properties of plant sterols
are similar in both men and women, although recent
studies highlight that plant sterols can diminish fat solu-
ble vitamins only in women[37]. Mixed gender studies
must possess the statistical power to separate men and
women as a statistical covariant, otherwise, the researcher
must assume an identical response across both sexes.
The recent study of Matvienko et al. [73] demonstrates
that soy sterol esters can effectively decrease LDL choles-
terol in young adults of age 23, suggesting age is not a very
critical variable influencing LDL cholesterol lowering
properties of plant sterols, as also confirmed in studies
with children [101]. In contrast, the meta-analysis of Law
[60] predicted that plant sterol and stanol esters would
reduce LDL cholesterol more effectively at each dose in
older compared with younger people. However, it should
be taken into consideration that older people had higher
starting circulating lipid levels, so the percent change did
not differ across age ranges. A number of studies have
shown that plant sterols effectively reduce blood choles-
terol in normocholesterolemic
[19,22,25,37,59,76,96,102,103], hypercholesterolemic
subjects [37,38,40,62,72,73,76,77,80,97,104-106], sub-
jects with familial hypercholesterolemia [78,100], and in
type II diabetic hypercholesterolemic patients [107,108].
Further, in a type II diabetic population consuming statin,
plant sterols had a combined effect on lowering LDL cho-
lesterol an additional 27%, the combined effect being
44% [108]. The reduction in LDL cholesterol seems to be
greater in hypercholesterolemic individuals with type II
diabetes. Plant sterols decreased LDL cholesterol in hyper-
cholesterolemic individuals with and without type II dia-
betes by 14.9 % and 29.8 %, respectively (Lau et al.
unpublished data).
Plant sterols are not recommended for pregnant or lactat-
ing women. However, there has not been a systematic
study testing this issue. Vegetarian women habitually con-
sume up to 500 mg of plant sterols per day. There is no
evidence that such women cannot have normal pregnan-
cies. Certain ethnic groups are known to have high levels
of plant sterol intake and their pregnancy outcome could
be evaluated in future studies. For example, in 372 semi-
acculturated Tarahumara Indians in the Sierra Madre
Occidental Mountains of Mexico, the diet was found to be
high in fiber and to contain less than 100 mg/day of cho-
lesterol and over 400 mg/day of plant sterols [4]. Further,
in the earlier stages of human evolution, some 5–7 mil-
lion years ago, plant sterol intake in Myocene diets would
have been considerably higher, up to 1 g/d [10]. Such
diets were not only rich in plant sterols, but also dietary
fiber, vegetable protein, and associated phytochemicals;
but low in saturated and trans-fatty acids [10]. To meet the
body's needs for cholesterol, genetic differences and poly-
morphisms were conserved by evolution, tending to raise
serum cholesterol levels.
Plant sterols likely interact with ATP-binding cassette
(ABC) transport proteins to direct cholesterol back into
the intestinal lumen, regulating absorption of cholesterol
and plant sterols [109-113]. Plat and Mensink [114] first
hypothesized that plant sterols increased the expression of
ABCA1. Thereafter, based on an animal study, it was sug-
gested that plant sterols are converted into a liver X recep-
tor (LXR) agonist, which activates the expression of ABC
proteins [115]. Mutations in ABC proteins are responsible
for the rare disease sitosterolemia [116]; and polymor-
phisms of ABC proteins may affect cholesterol absorption
based on a preliminary study [117]. Polymorphism of
ABCG8 gene was found to contribute to blood plant sterol
levels in healthy subjects [118] suggesting ABCG8 protein
regulates non-cholesterol sterol absorption.
Apolipoprotein E phenotype was originally shown to be
correlated with cholesterol absorption [119]. It wasLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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shown in one study [120] but not others [37,99] to affect
plant sterol cholesterol lowering efficacy in recent trials.
In addition to the above proteins, cholesterol absorption
is likely controlled by additional proteins [121], as well a
putative sterol transporter system [122]. In this context,
the genotype of apolipoprotein A-IV, scavenger receptor-
BI, 3-hydroxy-3-methyl-coenzyme A reductase, apolipo-
protein E, and cholesterol ester transfer did not affect cho-
lesterol lowering effects of plant stanol [122].
Plant sterols for children
Plant sterols are not recommended for normocholestero-
lemic children under five because children who are grow-
ing have a large need for cholesterol for normal
development. There is also the fear that plant sterols, par-
ticularly esters, could affect the absorption of fat soluble
vitamins. However, no direct evidence points at plant ster-
ols being in some way dangerous for children. Studies
with small amounts of plant sterols fed to infants have
shown that neonates have the adaptive ability to increase
their cholesterol synthesis [123-125]. In fact, infants are
typically fed formula diets containing cholesterol concen-
trations 3–35 times lower than breast milk, with consider-
ably higher levels of plant sterols [126]. There is the
possibility that cholesterol, received in utero or adminis-
tered to neonates, could affect gene expression and physi-
ology later in life. This theory was initially based on the
increased atherosclerosis incidence in adults fed formula
rather than breast milk as infants [127], as well as higher
cholesterol in men fed breast milk for less than 3 months
as compared to more than 9 months [128]. This so called
"cholesterol imprinting" hypothesis is now being
explored in controlled animal models with microarrays
[129]. Children with allergies to dairy routinely consume
vegetable oils rich in plant sterols and less cholesterol, and
thus have less cholesterol absorbed, but compensatory
increases in cholesterol synthesis [130].
Most studies examining the effects of plant sterols in chil-
dren have been conducted with hypercholesterolemic
children [131-134]. Generally, plant sterols seem to be as
effective in hypercholesterolemic children as in hypercho-
lesterolemic adults. Some older studies in children must
be interpreted with caution, as the preparations may have
been crystalline [135]. Becker [132], for example, found
that severely hypercholesterolemic children could be
effectively treated with sitosterol, and that 3 g/d sitosterol
combined with a half dose of bezafibrate was an effective
way to reduce the bezafibrate dose. Intake of 1.7 g/d of
plant sterols in ester form was effective in reducing total
cholesterol levels, LDL cholesterol and apo B levels in
children with familial hypercholesterolemia who fol-
lowed Step I diet without any adverse effects [136]. No
changes in concentration of lipid-adjusted carotenoids
were reported except for lycopene, which decreased by
8.1%. This decrease was considered of minor biological
and clinical importance[136]. The authors recommended
an increase in the intake of fruit and vegetables to avoid
the reduction in lycopene values when plant sterols were
introduced to Step I diet of children with familial
hypercholesterolemia.
In a crossover study, healthy 2–5 year old children con-
sumed either 3 g/d plant stanol ester or 5 g/d insoluble
wheat bran fiber for 2 weeks, then 10 g/d for the second
two weeks [101]. Relative to baseline, LDL cholesterol lev-
els were reduced 15.5% with stanol esters and 4% with the
fiber diet. Stanol esters did not affect triacylglycerols or
HDL cholesterol. The study showed that stanol esters
reduced LDL cholesterol in normocholesterolemic chil-
dren similarly to that found in normocholesterolemic
adults and hypercholesterolemic adults and children. In
healthy 6-year-old children who were on a low-saturated,
low-cholesterol diet, daily intake of 1.5 g/d of plant stanol
ester was effective in reducing total cholesterol and LDL
cholesterol values by 5.4% and 7.5%, respectively [137].
The intake of plant stanol did not cause any adverse clini-
cal effects, nor did it affect the levels of fat soluble vita-
mins; however, it did cause a 19% reduction in ratio of β-
carotene to LDL cholesterol ratio.
Children consuming vegetable oil sterols in margarine for
13 months had serum concentrations of campesterol and
sitosterol that were 75% and 44% higher than those in the
control children, while serum cholesterol precursor sterol
concentrations, indicative of cholesterol synthesis, did
not differ between the two groups [138]. Thus, doubling
dietary plant sterol intake almost doubles serum plant
sterol concentrations in 13-mo-old children, but has no
effect on endogenous cholesterol synthesis. Relative intes-
tinal absorption of natural plant sterols from the diet in
early childhood is similar to that in adults. In the older
study of Mellies et al. [139], 300–900 mg/d of plant ster-
ols led to a large accumulation of plant sterols in the
plasma (0.44 mM) of normo and hypercholesterolemic
children.
As in adults, in children, the apo E phenotype, could be a
factor affecting the efficacy of plant sterols. Plant sterols,
as an index of cholesterol absorption, were higher in
adults or children with the E4/3 phenotype as compared
with those with other phenotypes [140]. Lathosterol, an
index of cholesterol synthesis, was also higher in children
with E4/3 phenotype than in those with E3/3 or E3/2,
indicating these children both absorb and synthesize
more cholesterol [140]. The effect of phenotype of apo E
on response to sterol intake was investigated in 6-year-old
children [141]. Daily intake of 1.6 g of plant stanol was
effective in reducing blood cholesterol and LDLLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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cholesterol by 65 and 8%, respectively, in these children
regardless of apo E phenotype. Thus, children with differ-
ent apo E phenotype can achieve a reduction in their cho-
lesterol levels by intake of plant sterol.
From the previous studies, it is clear that plant sterols are
effective in reducing blood cholesterol in healthy as well
as in hypercholesterolemic children. The only side effect
reported is a reduction in levels in ratio of β-carotene to
LDL cholesterol ratio and lycopene values, which could be
balanced by increasing the intake of fruit and vegetable,
especially those rich in carotenoids, as was the case in
adult population [106].
Plant sterol intake and sitosterolemia
Sitosterolemia is a rare autosomal recessively inherited
disorder which results from absorption of high amounts
of plant sterol and cholesterol for unclear reasons linked
to a locus at chromosome 2p21 [142-144] leading to
development of coronary heart disease at young age, and
development of tendon xanthomatosis. Various candidate
genes involved in cholesterol absorption have been
excluded at present [145]. Sitosterolemic persons should
avoid food products containing plant sterols. Hydrogen-
ated plant sterols may be safer than non-hydrogenated
plant sterols for this population because the former is less
absorbed, however, this argument is speculative. A recent
study found that heterozygous subjects for sitosterolemia
who received sterol esters in a spread providing 3.3 g of
free sterol equivalents for 4 weeks, had a 10.6% reduction
in LDL cholesterol [146]. Levels of campesterol and sito-
sterol were increased, but the magnitude of the increase
was not much greater than that observed in normal sub-
jects consuming similar spreads. In another recent study
in 12 subjects who were obligate heterozygotes for sitoste-
rolemia, consumption of plant sterol ester for 6 weeks
resulted in an additional significant reduction of 5.9% in
LDL cholesterol over that provided by a Step I diet alone,
but no additional significant reduction was found after
consumption of plant sterol ester for 12 weeks [147].
Although plasma levels of plant sterols concentration
were elevated, the increase was similar to that reported in
normal and mildly hypercholesterolemic subjects who
consumed plant sterol esters [147]. The increase in plasma
levels of plant sterols reached a plateau, which indicates
that obligate heterozygotes eliminated the plant sterols
from their body in order to prevent their accumulation.
For prudency, it is nevertheless recommended that per-
sons with sitosterolemia avoid plant sterols.
Anti-atherogenicity activity
In vitro studies have shown that plant sterols are effective
in preventing hyperproliferation of vascular smooth mus-
cle cell that play a role in atherosclerosis development
[148]. Animal studies have shown that plant sterols also
have anti-atherogenicity activity. In rabbits, sitosatanol
feeding decreased plaque accumulation in coronary arter-
ies within the ascending aorta [149]. Feeding plant sterols
to apo E-deficient mice decreased platelet counts as well as
the susceptibility of red blood cells to hemolysis,
decreased plasma fibrinogen [16], and decreased forma-
tion of atherosclerotic lesions [15,16,150]. In healthy sub-
jects who consumed 4 g/d of wood based stanol ester, the
activity of antithrombin-III tended to increase compared
to control group [99]. Thus, plant sterols may reduce
atherosclerosis development not only by reducing blood
cholesterol levels but also by possessing anti-atherogenic-
ity activity.
Anti-cancer activity
The action of plant sterols as anticancer dietary compo-
nents has been recently extensively reviewed [151]. Plant
sterols can suppress tumor cell growth (LNCaP and HT-
29) [152,153]. Compared to cholesterol, β-sitosterol
caused a 24% decrease in cell growth and a 4-fold increase
in apoptosis. In the latter work, the authors were inter-
ested in the effects of β-sitosterol on the sphingomyelin
cycle, and measured two keys enzymes: protein phos-
phatase 2A (PP 2A) and phospholipase D (PLD). A 50%
increase was observed in PP 2A activity in media contain-
ing 16 µM of β-sitosterol; however, there were no changes
in protein levels of PP 2A. PLD activity increased in pres-
ence of phorbol myristate and β-sitosterol. This study sug-
gests that the sphingomyelin cycle, which increases cell
apoptosis, is mediated by PLD, PP 2A, and possibly, incor-
poration of β-sitosterol into the membrane. Another pos-
sible mechanism by which β-sitosterol can protect against
cancer is through down-regulation of cholesterol synthe-
sis, as was found in MDA-MB-231 human breast cancer
cells [14]. In an important in vivo study, SCID mice were
xenografted with the human breast cancer cell line MDA-
MB-231 [154]. Plant sterol-fed mice had a 33% smaller
tumor size and 20% less metastases in lymph nodes and
lungs than cholesterol-fed mice. This finding implied the
possibility that plant sterols may retard the growth and
spread of breast cancer cells. In addition to retarding the
growth of breast cancer cells by plant sterols, there is some
evidence that plant sterols can affect the development of
prostate cancer [155]. In a meta-analysis, 519 men were
studied in 4 randomized, placebo-controlled, double-
blind trials. β-sitosterol improved urinary symptom scores
and flow measures, suggesting that non-glucosidic forms
of β-sitosterol improve urinary symptoms and flow meas-
ures. Long term effectiveness, safety, and ability to prevent
benign prostatic hyperplasia complications are not
known [155]. In another recent study, there was no evi-
dence that plant sterol usage at dose of 300 mg/d,
decreased risk of colon and rectal cancers [156]. A similar
conclusion was reached following a rat study in which ratsLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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were given the carcinogen methyl-nitroso-urea and then
monitored for tumor development [157].
Plant sterols have also been found to have a protective
effect against lung cancer [158]. In this study, intake of
about 144 mg/d of plant sterols was associated with
reduction in risk for lung cancer even after controlling of
confounding factors, i.e. tobacco smoking, vegetables,
fruits, and antioxidant substances. Total dietary plant
sterol intake was found to be inversely associated with
breast [159]), stomach [160], and esophageal [161] can-
cers. It was found that women with highest quartiles of
total dietary intakes of plant sterols (>122 mg/d) had
reduced risk of endometrial cancer [162], and intake of
more than 521 mg/d reduced risk of ovarian cancer [163].
On the other hand, in a prospective epidemiological
study, high dietary intake was not associated with reduced
risk of colon and rectal cancers [156]. However, the intake
of plant sterol might reduce the risk of more than one type
of cancer.
Anti-inflammation activity of plant sterols
Bouic [17] and Bouic et al [164] have reviewed the possi-
ble roles of phytosterols in the etiology or preventive role
of phytosterols in various diseases and conditions, includ-
ing proliferative responses of lymphocytes, pulmonary
tuberculosis, feline immunodeficiency virus and HIV,
stress induced immune suppression, rheumatoid arthritis,
and allergic rhinitis/sinusitis. The mechanisms by which
plant sterols display their anti-inflammatory activity are
thought to include inhibition of secretion of inflamma-
tory mediators such as interleukin-6, and tumor necrosis
factor-α by monocytes [17]. Most of the work has been
conducted with animals. From these provocative results, it
is not unlikely that plant sterols will be further used for
purposes related to control of deveopment and spread of
certain cancers in humans.
Anti-oxidant activity
Another possible effect of plant sterols is their antioxidant
activity [165]. It was found that the methanol extract of
soybean oil, which has a strong in-vitro protective effect
against DNA damage in human endothelial cell, contains
phytosterols in addition to tocopherols and n-3 polyun-
saturated fatty acids (PUFA). Results suggest that the anti-
oxidant activity of soybean oil may be in part related to
sterol content. Moreover, in in-vitro conditions, sitosterol,
and sitosterol glucoside were found to decrease lipid per-
oxidation of platelet membranes in the presence of iron
[18] and in healthy human subjects a 2 and 3-g dose of
stanol ester reduced oxidized LDL-C levels [82]. The
authors suggested that the intake of stanol ester might
protect LDL particles from oxidation. Thus, based on
results from in vitro studies and on human study, there is
a possibility that plant sterols may possess antioxidant
properties. Such antioxidant protection could also benefit
atherosclerosis [166] and cancer [167] disease state.
Anti-ulcer activity
In a recent study, phytosterol esters, but not sterols, in
horse gram (an herb in the genus Dolichos cultivated in
India for food and fodder) were protective in a pyloric
ligation model of ulcer, whereas sterols were protective in
acute ulcer models using ethanol-induced and cysteam-
ine-induced ulceration [168]. Phospholipids were protec-
tive in both types of model. Thus, the presence of sterols,
sterol esters, and phospholipids in food lipids in staple
diets may account for the low prevalence of duodenal
ulcer in certain geographical areas, despite a uniformly
high prevalence of Helicobacter pylori infection.
Anti-fungal activity
Another area for future investigation is the anti-fungal
activity of plant sterols and related triterpenes [169]. In
this work, the anti-fungal activity of triterpenes in the
mushroom species Ganoderma annulare was
demonstrated.
Safety
It has been concluded that plant sterols, within the range
that causes desirable reduction in blood levels of total
cholesterol and LDL-cholesterol, are clinically safe. This
conclusion has been reported in short-term studies
[19,39,40,170] as well as in long-term study that lasted for
1 year [81]. Since plant sterols decrease the absorption of
cholesterol, they might also affect the absorption of fat-
soluble vitamins. The scientific evidence for the impact of
phytosterols on carotenoid status and fat soluble vitamins
is summarized in Table 3. The effect of plant sterols on the
blood levels of precursors of fat-soluble vitamins is a con-
troversial issue. In some studies, plant sterols consump-
tion has been shown to significantly reduce levels of
carotenoids [25,37,38,81,170,171], tocopherol [37], and
lycopene [25,38]. Other studies reported that the con-
sumption of plant sterols does not affect blood levels of
carotenoids [39,72,104,172], tocopherol [19,39,173],
and lycopene [19,173].
In a recent trial comparing equal free sterol equivalent
amounts (2.2 g/d) of esterified sterols and free sterols in
milk, both forms of sterols decreased the absorption of β-
carotene and α-tocopherol in normocholesterolemic
men. The reduction in β-carotene bioavailability was sig-
nificantly less pronounced with free plant sterols than
with plant sterol esters However, there was no difference
in cholesterol absorption between the two forms of plant
sterols. [71]. Esters are presumed to have more of an effect
on fat soluble vitamins because they partition into the oil
phase of the intestine, whereas free sterol would partition
into the micellar phase [174].Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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Table 3: Summary of scientific evidence for the impact of phytosterols on carotenoid status and fat soluble vitamins
Reference Products Vehicle Subject Mean 
Age or range
Condition: Starting 
mean TC mM (range)
Dose g/day 
(free sterol/
stanol 
equivalents)
Duration of 
study wks
Outcome
Impact of 
phytosterols on 
vitamin A and 
carotenoid status
Impact of 
phytosterols on 
other fat soluble 
vitamins
[25] C,  D2,  D3, 
D5
Spread Adults, 18–65 <8 1.5–3.3 3.5 ↓ absolute and lipid 
standardized levels of α- 
and β-carotene and 
lycopene.
[178] D1 Spread, 
Butter
Postmenopausal 
women aged 
50–55
5.5–8.0 3.2-D1 in 
spread; 2.4-D1 
in butter
Margarine 
intervention-
6 wks; butter 
interventio-5 
wks
↔ Serum retinol
↓ α- and β-carotene 
concentrations
↔ Serum vitamin D
↔ lipid 
standardized α-
tocopherol
[181] D Spread Adults Moderately 
hypercholesterolemic
8 ↔ retinol
↓ α- and β-carotenes
↔ vitamin D
↔ ratio of α-
tocopherol to 
cholesterol
[62]  D1, D2 Spread Adults 5.4–7.5 2.3-D1; 2.2-D2 8 ↓ β-carotene
↔ β-carotene
↔ α-carotene with or 
without lipid adjustment
[19]  C2 Spread Adults, aged 19–
58
<7.5 0.9, 1.6 and 3.3 3.6 ↓ α and β carotene and 
lycopene concentrations 
reduced
↔ lipid-adjusted 
carotene levels
↓ α-tocopherol 
concentrations 
reduced
↔ lipid 
standardized α 
tocopherol
[41]  D Spread Adults Hypercholesterolemic 1 g 3x/d (2 
different 
formulations) or 
2 g 3x/d
8 ↔ vitamin A ↔ vitamin D
[20]  C2, C3 Spread Adults aged 18–
62
<8 0.8 9 ↓ lycopene
↔ α- and β-carotene
[76]  C, D Spread Adults, mean 
age 49
4.8–7.0 2.0 4 ↔ retinol
↔ α carotene or 
lycopene 
concentrations, with or 
without lipid 
adjustment.
↓ β-carotene decreased 
after each intervention, 
but not when lipid 
adjusted
↔ vitamin D 
concentration with 
or without lipid 
adjustment.
[96] D Spread, 
Shortenin
g
Adults aged 18–
65
<6.5 2.5 g/d-lunch or 
in 3 doses of 
0.4-breakfast, 
0.8-lunch and 
1.3-dinner
4 ↔ retinol
↔ α-carotene
↓ lycopene and β-
carotene after the 3x/d 
regime
↓ β-carotene by 1x/d 
regime
↔ in any of the lipid-
adjusted concentrations
↓ α-tocophorol 
after both the 1x 
and 3x/d regime 1x/
d regime, ↔ in 
lipid-adjusted 
concentrations
[137]  D Spread Children, aged 6 Healthy 1.5 12 ↓ β-carotene with and 
without lipid 
standardization
↓ α-tocopherol but 
↔ in lipid-adjusted 
concentration
[134] D Spread 24  children  aged 
3–13; 4 parents; 
16 healthy family 
members
Familial 
hypercholesterolemia
2.2 12 ↔ retinol
↓ α and β-carotenes 
with and without lipid-
adjustment 
(measurements done 
only in children)Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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During plant sterol consumption, increasing the con-
sumption of fruits and vegetables to be > five servings and
including one or more carotenoid rich source would be
enough to avoid reduction in carotenoid levels resulted
from plant sterol intake [106].
Conclusions
Based on the positive results from studies examining the
effects of low doses of free plant sterols and sterol esters,
there is a good likelihood that a minimum dose of 0.8–
1.0 g of free sterol and free sterol equivalents will reduce
LDL cholesterol by 5% or more, and that this reduction in
[39]  C Spread Adults 25–64 >5.8 1.5 or 3.0 24 ↔ retinol, α-carotene 
or β-carotene
[170] C Spread, 
Salad 
Dressing
Healthy adults 3.0, 6.0 or 9.0 8 ↓ α and trans β-
carotene reduced in the 
9.0 g/day group, but all 
carotenoid values 
remained within the 
normal range
All fat soluble 
vitamins remained 
within normal range 
after treatments
[38]  C Spread Adults, aged 21–
75
3.4–5.0 1.1 or 2.2 5 ↔ in serum retinol, 
zeaxanthin or 
cryptoxanthin
↓ trans β-carotene, α-
carotene, lycopene and 
lutein all decreased
↓ lipid-adjusted trans β-
carotene
↔ α- or γ-
tocopherol, 25 
hydroxyvitamin D 
or phylloquinone
[40] C Yogurt-
drink
Adults, aged 33–
69
Modertally 
hypercholesterolemic
14 ↔ vitamin A ↔ vitamin E, ↑ 
vitamin D (probably 
as a result of 
increased skin 
synthesis of vitamin 
D due to the time 
of year)
[70] C Yogurt Adults Normocholesterolemic 3 4 ↓ β-carotene ↑ lipid standardized 
tocopherol
[79] C Spread Healthy  adults 1.8 3 ↔ vitamin A
↓ β-carotene
↔ vitamin E
[173]  C, D Spread Adults Hypercholesterolemic 1.9-C 1.8-D 3 ↔↔
[81]  C Adults aged 48 Normocholesterolemic 
and 
hypercholesterolemic
1.6 52 ↓ lipid-adjusted α-and β-
carotene
↔ lipid-adjusted fat 
soluble vitamin 
concentration
[71] A2,  C2 Vegetable 
oil, partly 
filled milk
Men aged 29 <5.2 2.2 1 ↓ β-carotene 
bioavailability 57% with 
C2, 48% with A2; ↓ 
TRL-retinyl palmitate 
bioavailability 48% with 
C2, 32% with A2. No 
standardization to TAG 
because TRL-TAG 
pharmacokinetics were 
equivalent in all groups
↓ α-tocopherol 
bioavailability 27% 
with C2, no efffect 
with A2
[42] A2 Vegetable 
oil, partly 
filled milk
Adults, aged 60 7.0 1.2 or 1.6 4 wk/period ↓ α- and β-carotene, 
lycopene, and lutein 
with 1.6 g dose only.
↔ lipid-adjusted α- and 
β-carotene, lycopene, β-
cryptoxanthin, 
zeaxanthin with either 
dose.
↓ lipid-adjusted % 
change in lutein with 1.6 
g
↓ α-tocopherol 
with both doses
↔ lipid-adjusted α-
tocopherol with 
both doses
See Table 1 for abbreviations. TAG, triacylglycerol; TRL, triacylglycerol-rich lipoprotein.
Table 3: Summary of scientific evidence for the impact of phytosterols on carotenoid status and fat soluble vitamins (Continued)Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/5
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LDL cholesterol will correlate with an approximate 6–
10% reduction in coronary heart disease risk at age 70
[35,36]. There is also a good likelihood that the reduction
in LDL cholesterol within this same dosage could be
higher if full compliance of the plant sterol dosage were
assured. In studies where subjects were monitored to
ensure full compliance, efficacy with a 1.5 to 2 g/d dose
ranged from 12–16%. For maximum efficacy of free plant
sterols, the plant sterols must be administered in a soluble
or microcrystalline form. Efforts must be taken to assure
that the free plants sterols remain in this bio-efficacious
form during the shelf life of the product. Our dosage rec-
ommendation of 0.8–1.0 g of free sterol and free sterol
equivalents compares favorably with the FDA interim
final rule 21 CFR 101.83 recommending 0.65 g of sterol
esters per serving, twice per day in spreads, which is equiv-
alent to 0.8 g of free sterol equivalents per day. As of Jan-
uary 2003, the FDA recognized that the scientific literature
supports expanding the health claim to include free forms
of plant sterols and stanols, and to include a wider range
of products, including low-fat products. The FDA further
stated that the science (as of January 2003) shows that the
lowest effective daily intake of free phytosterols is 800 mg/
d http://vm.cfsan.fda.gov/~dms/ds-ltr30.html.
In addition to their cholesterol lowering properties, plant
sterols have other promising effects, including anti-can-
cer, anti-inflammation, anti-atherogenicity, and anti-oxi-
dation activities. Despite the fact that plant sterols reduce
the carotenoid levels in adults, it seems that an intake of
plant sterols between 0.8–1.0 g is essential to prevent
chronic diseases in adult population. The carotenoid low-
ering effect of plant sterols can be corrected by increasing
intake of food that is rich in carotenoids. However, more
studies are needed in pregnant and lactating women as
well as on children in order to verify the dose required to
decrease blood cholesterol without affecting fat-soluble
vitamins and carotenoid status.
Plant sterols are naturally occurring molecules that
humanity has evolved with, which partially counter the
absorption of dietary cholesterol and have other impor-
tant biological functions described above. The myriad of
factors that can affect the efficacy of plant sterols have
been explored. The resonating conclusion is that properly
solubilized 4-desmetyl plant sterols, in ester or free form,
in reasonable doses (0.8–1.0 g of equivalents per day) and
in various vehicles including natural sources, and as part
of a healthy diet and lifestyle, are important dietary com-
ponents for maintaining good heart health. Consumption
from natural sources should be encouraged for all per-
sons, and consumption of plant sterols in enriched
sources should be encouraged following consultation
with a clinician. The clinician should be assured that the
individual is a responder to plant sterols, and achieves a
reduction in LDL cholesterol. Along these lines, it would
be fruitful to monitor individuals for markers of choles-
terol absorption before recommending consumption of
enriched plant sterols. Those persons who are poor
absorbers of dietary cholesterol (on the basis of low levels
of serum cholestanol and plant sterols) [175] may not be
ideal candidates for consuming plant sterols to lower
plasma LDL cholesterol, but may still benefit from plant
sterols' other positive effects.
List of abbreviations
ABC, ATP-binding cassette; apo, apolipoprotein; LDL,
Low density lipoprotein; PLD, phospholipase D; PUFA,
polyunsaturated fatty acids.
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